| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
L-Leucine-d3 does not have a distinct pharmacological target separate from natural L-leucine. L-Leucine is an essential branched-chain amino acid (BCAA) that acts as a nutrient signal to stimulate protein synthesis and activates the mTOR signaling pathway.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope-labeled compound, L-Leucine-d3 does not exhibit pharmacological activity distinct from that of natural L-leucine. The deuterium labeling does not alter the biological activity of L-leucine. L-Leucine itself is an essential amino acid that activates the mTOR signaling pathway and stimulates protein synthesis. |
| ln Vivo |
L-Leucine-d3 is not used as a pharmacologically active compound in vivo. It is used as an internal standard and tracer in metabolic studies to quantify leucine levels and study protein metabolism.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for L-Leucine-d3 are not typically performed, as the compound is used as an analytical standard rather than a pharmacological modulator.
|
| Cell Assay |
L-Leucine-d3 is used as an internal standard in cell-based assays for the quantification of leucine. The compound is added to cell culture media or cell lysates, and the concentration of leucine is measured by mass spectrometry.
|
| Animal Protocol |
L-Leucine-d3 is used as an internal standard in in vivo pharmacokinetic and metabolic studies in animals. The compound is administered to animals, and blood, tissues, and urine are collected at various time points and analyzed by mass spectrometry to quantify leucine levels and study protein metabolism.
|
| ADME/Pharmacokinetics |
L-Leucine-d3 is used as an internal standard for the quantification of leucine in biological matrices using GC-MS or LC-MS. As a deuterated compound, it exhibits practically identical chemical properties to unlabeled leucine, making it an ideal internal standard. Its use improves the accuracy and precision of analytical methods by correcting for variations in sample preparation, injection volume, and ionization efficiency.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for L-Leucine-d3. As a stable isotope-labeled form of the essential amino acid L-leucine, the compound is expected to have a low toxicity profile similar to that of natural L-leucine. L-Leucine is generally well-tolerated at physiological concentrations.
|
| References | |
| Additional Infomation |
L-Leucine-d3 is a compound of L-leucine and deuterated form.
L-Leucine-d3 is a deuterium-labeled form of the essential amino acid L-leucine, where three hydrogen atoms are replaced with deuterium. It is used as an internal standard for the quantification of leucine by GC-MS or LC-MS and as a tracer for studying protein metabolism. L-Leucine is an essential branched-chain amino acid that activates the mTOR signaling pathway and stimulates protein synthesis. The compound is not a drug and is strictly for research purposes. |
| Molecular Formula |
C6H10D3NO2
|
|---|---|
| Molecular Weight |
134.19
|
| Exact Mass |
134.113
|
| CAS # |
87828-86-2
|
| Related CAS # |
L-Leucine;61-90-5
|
| PubChem CID |
11073472
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
225.8±23.0 °C at 760 mmHg
|
| Melting Point |
>300ºC(lit.)
|
| Flash Point |
90.3±22.6 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
0.73
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C([2H])([2H])C(C)C[C@@H](C(=O)O)N
|
| InChi Key |
ROHFNLRQFUQHCH-LONBSJBQSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1/i1D3/t4?,5-
|
| Chemical Name |
(2S)-2-amino-5,5,5-trideuterio-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 10 mg/mL (74.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.4521 mL | 37.2606 mL | 74.5212 mL | |
| 5 mM | 1.4904 mL | 7.4521 mL | 14.9042 mL | |
| 10 mM | 0.7452 mL | 3.7261 mL | 7.4521 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
